hVIVO Reports H1 Revenue Dip but Upgrades Full-Year EBITDA Outlook Amid Diversification Push

hVIVO’s Half-Year: Navigating Headwinds While Laying Groundwork for Future Growth

Right, let’s dissect hVIVO’s latest trading update. On the surface, the headline numbers show a company navigating some choppy waters. Dig deeper, however, and there’s a compelling narrative of strategic diversification and underlying resilience that paints a more encouraging picture for the future. This isn’t just about weathering a storm; it’s about building a stronger ship.

The H1 2025 Snapshot: Expected Dip, Controlled Burn

• Revenue: £24.2 million (H1 2024: £35.6 million). A significant drop, yes, but crucially flagged as in line with full-year expectations of £47 million. This suggests the bulk of revenue is weighted towards H2, which isn’t uncommon in project-based CRO work.
• EBITDA Margin (pre-exceptionals): Approximately 12% (H1 2024: 24.5%). Reflective of lower revenue volumes but bolstered by operational efficiencies, cost management, and cancellation fees.
• Cash Position: £23.3 million (June 2024: £37.1 million). The decrease is largely attributable to the strategic acquisitions of CRS and Cryostore (£10.5 million net). Importantly, the company remains debt-free.
• Contracted Orderbook (Weighted): £40 million (June 2024: £71 million). A notable reduction, signalling the impact of current market conditions.

The revenue and orderbook figures starkly illustrate the persistent headwinds management highlighted: a subdued biotech funding environment, particularly in the US, leading to delayed conversions, cancellations, and postponements across the broader CRO sector. This isn’t an hVIVO-specific problem; it’s an industry-wide squeeze.

The Silver Linings & Strategic Shifts

Where this update gets genuinely interesting is in the proactive steps hVIVO is taking and the green shoots emerging despite the tough climate:

1. Diversification Paying Early Dividends

• The acquisitions of CRS (Clinical Research Services) and Cryostore, completed in H1, contributed £5.5 million to group revenue (£5.2m and £0.3m respectively). This is new revenue from new services.
• CRS integration is reportedly “on track,” and crucially, sales synergies are already being realised through cross-selling, with the first such deal signed in H1. The aggregate value of CRS customer proposals grew 60% year-on-year – a strong indicator of business development traction.
• Beyond acquisitions, the group highlighted progress with its clinical site network and hLAB services, and successfully executed its largest field trial and largest laboratory contract to date. Automation projects are underway to drive efficiencies.

This isn’t just tinkering; it’s a fundamental shift. hVIVO is actively moving beyond its core (albeit world-leading) Human Challenge Trial (HCT) niche. It’s building a broader, more resilient full-service early-stage CRO platform, now active in cardiometabolic (e.g., obesity) and respiratory diseases alongside infectious diseases. The Board explicitly states the company is now “more diversified” and serving a “broader client base,” positioning it as a “unique provider in the European clinical services sector.”

2. Upgraded Full-Year Outlook

Perhaps the most concrete positive signal is the upgrade to full-year EBITDA guidance. Previously expecting a mid-single digit EBITDA loss (pre-exceptionals), management now forecasts a low-single digit loss. While still a loss, this improvement reflects the impact of cost controls, operational efficiencies, and the early contributions from diversification. Revenue guidance of £47 million is reaffirmed, heavily reliant on a strong H2 performance.

3. Pipeline Strength Offers Hope

Despite the lower current orderbook, management is vocal about a strong sales pipeline:

• “Advanced discussions” are underway for “a number of major HCT projects” across various pathogens, some potentially being the group’s “largest ever value contracts.”
• Significant opportunities are also being pursued for hLAB and clinical services.
• The aggregate value of customer proposals submitted in H1 2025 has already surpassed the entirety of FY 2024.
• There’s a “substantial pipeline of opportunities in discussion which are not yet contracted.”

The Board firmly believes the sector’s issues are “transitory rather than fundamental.” Their confidence hinges on an expected normalisation of the market and improvement in biotech funding, upon which hVIVO’s reputation and service quality should allow it to capitalise strongly.

Governance & Looking Ahead

• New Chair Imminent: The Nominations Committee has a preferred candidate for Independent Non-Executive Chair, described as having “substantial sector-relevant experience and expertise.” An announcement is pending due diligence. This brings fresh perspective at a key strategic juncture.
• Management Confidence: CEO Yamin ‘Mo’ Khan struck a balanced but ultimately confident tone: “Our diversification strategy is already delivering results… We believe that we are well positioned to deliver growth in FY26.” The focus is firmly on executing the strategy and converting the pipeline as market conditions improve.

The Takeaway: Building for the Upswing

hVIVO’s H1 results reflect the undeniable pressure facing its core biotech clients and the wider CRO sector. Revenue and orderbook declines are real. However, the strategic response – aggressive diversification through acquisition and service expansion, coupled with tight cost control – appears to be yielding early results. The upgraded EBITDA guidance and the emphatic statements about a burgeoning sales pipeline are significant positives.

This feels like a company investing through the downturn, positioning itself for a much broader market when the funding cycle turns. The transition isn’t painless (the EBITDA loss confirms that), but the pieces are being assembled for a potentially stronger, more diversified, and resilient hVIVO. The message for investors is one of near-term challenge but increasing confidence in the medium-term growth trajectory, starting in FY26. The key will be converting that substantial pipeline into contracted backlog as market conditions permit. One to watch closely, especially for updates on those “major HCT projects” in advanced talks.